Equities

Pangaea Oncology SA

PANG:MCE

Pangaea Oncology SA

Actions
  • Price (EUR)1.77
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change-21.68%
  • Beta0.1326
Data delayed at least 15 minutes, as of Sep 20 2024 11:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.

  • Revenue in EUR (TTM)4.66m
  • Net income in EUR-2.70m
  • Incorporated2007
  • Employees62.00
  • Location
    Pangaea Oncology SAQuiron Dexeus University HospitalC/ Sabino Arana, 5-19BARCELONA 08028SpainESP
  • Phone+34 934097981
  • Fax+34 935460172
  • Websitehttps://www.panoncology.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gensight Biologics SA1.27m-26.22m40.82m16.00------32.22-0.5427-0.54270.0269-0.47260.0723--2,534.0079,187.50-149.52-79.44---144.54-----2,069.53-1,036.27---------50.93--5.09---58.28--
Abionyx Pharma SA4.64m-3.52m46.81m61.00--5.45--10.09-0.121-0.1210.15810.2460.302721.864.2076,694.22-22.95-18.82-32.52-28.8713.3214.32-75.82-128.541.70--0.2997---11.6592.8416.36--41.40--
Saniona AB2.19m-7.20m47.31m22.00--77.48--21.60-0.9821-0.98210.28220.06230.2386--6.231,081,652.00-78.47-59.16-168.78-70.15-92.01-970.05-328.83-1,483.55---3.030.8668--10.19-21.0554.71---34.94--
Cantargia AB0.00-20.07m50.79m23.00--6.37-----1.29-1.290.000.49320.00----0.00-98.38-55.08-129.99-61.35------------0.00------24.69------
Molecure SA84.36k-5.13m55.13m112.00--2.50--653.47-1.35-1.350.02235.590.003--0.07413,244.87-18.172.64-19.292.76-444.0197.54-6,082.4012.84----0.0657---18.85237.24-19.67---24.82--
Promimic AB3.60m-919.90k57.17m17.00--9.15--15.87-0.563-0.5632.213.800.4828-3.883.922,406,824.00-12.33-24.89-14.16-29.25104.60101.23-25.54-89.474.51--0.00--128.63--41.95------
Intellego Technologies AB20.36m7.30m58.01m62.008.253.057.282.853.033.038.508.200.82984.242.453,729,807.0029.74--37.90--68.61--35.83--1.888.840.1532--222.74--493.56------
Poolbeg Pharma PLC0.00-4.69m58.18m8.00--3.38-----0.0079-0.00790.000.02890.00----0.00-22.65---24.00--------------0.00------16.11------
4Sc AG359.00k-7.53m59.11m15.00--50.02--164.65-0.7444-0.74440.03550.10840.0385--3.2923,933.33-80.73-39.49-134.75-42.8479.6792.24-2,097.22-337.74----0.00---30.28-40.7842.64---56.05--
Poltreg SA140.53k-4.08m59.64m23.00--3.21--424.37-3.74-3.740.128717.040.005127.123.2226,373.63-14.82-6.51-16.41-7.35-1,804.83-391.38-2,903.50-449.244.21--0.0913--40.04---588.92--214.26--
Novacyt SA13.82m-33.18m59.84m270.00--0.5743--4.33-0.4698-0.47810.19571.480.08432.600.440651,180.70-20.2410.94-25.1714.4932.2161.98-240.0917.642.82--0.1419---44.97-0.9408-25.22--2.09--
Pangaea Oncology SA4.66m-2.70m60.91m62.00--2.65--13.06-0.0898-0.08980.15570.66910.16013.861.2376,449.51-9.46-11.40-10.90-14.6238.9279.42-59.10-57.872.57--0.1054---5.1110.75-322.51---33.46--
Mabion SA32.76m8.76m63.44m226.007.251.865.881.942.312.318.659.010.75384.0217.35618,836.3020.15-7.1925.09-16.7978.3058.1026.73-14.271.64101.630.026---7.50--77.94--40.86--
BIOTON SA43.64m-1.60m67.97m358.00--0.484911.261.56-0.0797-0.07972.176.970.23031.0221.19520,435.80-0.8464-1.99-1.04-2.4733.8045.33-3.67-8.610.20850.32950.0864---22.10-5.5160.10-38.690.3284--
Arcticzymes Technologies ASA9.92m1.25m75.69m68.0060.492.7842.697.630.28670.28672.276.240.34850.53496.831,706,250.004.3915.584.6317.2294.3996.6912.6033.2317.25--0.02980.00-13.1612.24-40.89--47.93--
Data as of Sep 20 2024. Currency figures normalised to Pangaea Oncology SA's reporting currency: Euro EUR

Institutional shareholders

1.24%Per cent of shares held by top holders
HolderShares% Held
Santander Private Banking Gestion SA SGIICas of 30 Jun 2024425.54k1.24%
Renta 4 Gestora SGIIC SAas of 30 Jun 20240.000.00%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.